DLL3 CAR-T Therapy Targeting Brain Tumors

This study is testing a new type of immune cell therapy called DLL3-targeted CAR-T cells in people with brain tumors (such as glioblastoma) that have come back or are no longer responding to standard treatments. CAR-T therapy involves re-engineering a patient's own immune cells to attack the tumor. **You may be eligible if...** - You are between 2 and 70 years old - You have a brain tumor that has recurred or is not responding to treatment, and you have already completed standard treatment (surgery, radiation, and chemotherapy) - Your tumor can be measured on imaging - You have a reasonable level of physical function (Karnofsky score of 60 or higher) - Your blood counts and organ function are within acceptable limits **You may NOT be eligible if...** - You are on high-dose steroids (more than 4 mg/day dexamethasone) - You have serious infections, severe organ problems, or other active cancers - You have a life expectancy of less than 3 months Talk to your doctor to see if this trial is right for you.